Juan Carlos Alonso Farto

Juan Carlos Alonso Farto

Auto-generated profile, based on publicly available information

Juan Carlos Alonso Farto

Servicio de Medicina Nuclear, Hospital General Universitario Gregorio Marañón, Madrid, España

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JAJ. C. Alonso
J. C. Alonso
ICI. Casans
I. Casans
FGF. M. González
F. M. González
DFD. Fuster
D. Fuster
ARA. Rodríguez
A. Rodríguez
NCNataly Espinoza Cámac
Nataly Espinoza Cámac
Background: Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods: The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results: Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AWAbimbola O Williams
Abimbola O Williams
JAJuan Carlos Alonso-Farto
Juan Carlos Alonso-Farto
ICIrene Casáns-Tormo
Irene Casáns-Tormo
ARAntonio Rodríguez-Fernández
Antonio Rodríguez-Fernández
DFDavid Fuster
David Fuster
IOItziar Oyagüez
Itziar Oyagüez
E16159 Background: Evidence synthesis can be used to demonstrate the economic value of medical technologies. Transarterial radioembolization (TARE) is a clinically effective therapy for hepatocellular carcinoma (HCC); however, a synthesis of the comparative economic outcomes is lacking. This study systematically reviewed and summarized the available economic evaluations of TARE for the treatment of HCC. Methods: A systematic review of economic evaluations of TARE for HCC treatment following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was performed. English and Spanish publications were identified from PubMed, Embase, Cochrane, MEDES, health technology assessment agencies, and scientific congress databases published through May 2021. Results: Among 423 records screened, 20 economic evaluations (two cost-effectiveness analyses (CEAs), eight cost-utility analyses (CUAs), one cost-minimization analysis, six cost analyses, and three budget impact analyses) met the pre-defined criteria for inclusion. Included studies were evaluated from a payer perspective (n = 20) and included both payer and societal perspectives (n = 2). Thirteen studies were published from a European perspective, six from the United States, and one from the Canadian perspective. Included studies evaluated early (n = 4) vs. intermediate and advanced HCC (n = 15). TheraSphere and Sir-Spheres were the most evaluated TARE therapies compared to transarterial chemoembolization (TACE) (n = 12) alone or TACE/sorafenib agents (n = 10). The time horizon in the included studies varied: TARE vs. sorafenib (5-years and lifetime) and TARE vs. TACE (5-years). Variability in health outcomes was observed with greater health benefits reported for TARE vs. TACE for intermediate (n = 1) and advanced-stage patients (n = 2) and TARE vs. sorafenib for intermediate (n = 1) and advanced-stage patients (n = 6). All CEAs compared the costs and survival benefits of TARE vs. TACE/Transarterial embolization (TAE)/sorafenib/tyrosine-kinase inhibitor. Of the 20 studies, TARE was associated with lower treatment costs in ten studies. From the payer perspective, TARE costs varied widely in the Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from $1,770 (BCLC-A) to $66,800 (BCLC-C). The life-years gained (LYG) ranged from 1.1 years (TARE vs. sorafenib/lenvatinib) to 3.1 years (TARE vs. TACE/TAE/drug-eluting bead-TACE). The incremental cost-utility ratio (ICUR) for TARE vs. sorafenib ranged from $38,352/QALY to $71,386 (dominant) and one CUA of TARE vs. TACE and showed an ICUR of $22,181/QALY. Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term treatment for HCC, driven by increased LYG compared to other HCC therapies.

21 November 2022 in Revista Española de Medicina Nuclear e Imagen Molecular
Verified
Journal Article
Closed access
AHA. Marí Hualde
A. Marí Hualde
JMJ. Ardila Mantilla
J. Ardila Mantilla
JRJ. Orcajo Rincón
J. Orcajo Rincón
ARA. Rotger Regí
A. Rotger Regí
MKMartha Kestler
Martha Kestler
JFJ.C. Alonso Farto
J.C. Alonso Farto

20 November 2012 in Circulation
Verified
Journal Article
Closed access
RSRicardo Sanz-Ruiz
Ricardo Sanz-Ruiz
EGEnrique Gutiérrez-Ibañes
Enrique Gutiérrez-Ibañes
EDEsther Pérez David
Esther Pérez David
JFJuan Carlos Alonso Farto
Juan Carlos Alonso Farto
JCJaime Elizaga Corrales
Jaime Elizaga Corrales
FFFrancisco Fernández-Avilés
Francisco Fernández-Avilés
Introduction: electromechanical mapping (EMM) of the left ventricle (LV) is a new technique that provides us with voltage (unipolar and bipolar voltage) and contractility (lineal local shortening) information of the LV. The objective of this study was to assess the correlation between EMM parameters and myocardial perfusion and contractility by SPECT/MRI, in patients with advanced chronic coronary artery disease (CAD). Methods: the PRECISE clinical trial of freshly isolated adipose-derived stem cells for angiogenesis included pts with chronic stable CAD, reversible perfusion defects detectable by SPECT and not amenable for revascularization. Wall motion score index was assessed with MRI imaging in all patients (normal=1; hypokinetic=2; akinetic=3). Perfusion was studied with SPECT Tc-99m sestamibi (normal=grade 0; most impaired=grade 4) and EMM was performed with the NOGA XP system, all using the same 17-segment polar map of the LV. All studies were performed and analyzed by independent observers blinded to the results of the other techniques. Results: 27 consecutive pts were included (62±8 years and 77% male). A total of 865 SPECT and MRI segments were correlated with the corresponding EMM data. Segments with better perfusion at rest and stress (fig.1), and segments with better WMSI by MRI (fig.2) had better voltage and local shortening parameters. Conclusions: EMM is a useful technique for assessing myocardial health status in terms of perfusion and contractility in chronic CAD pts, and can be used for a precise delivery of stem cell therapy.